Ser386
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser386  -  DUSP4 (human)

Site Information
SSLPYLHsPITTsPS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15412243

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
gastric cancer ( 3 , 4 ) , gastric carcinoma ( 3 , 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 1 )
Treatments:
LPS ( 1 ) , Su11274 ( 2 ) , U0126 ( 1 )

Downstream Regulation
Effects of modification on DUSP4:
protein stabilization ( 1 )

References 

1

Crowell S, et al. (2014) Post-translational Regulation of Mitogen-activated Protein Kinase Phosphatase (MKP)-1 and MKP-2 in Macrophages Following Lipopolysaccharide Stimulation: THE ROLE OF THE C TERMINI OF THE PHOSPHATASES IN DETERMINING THEIR STABILITY. J Biol Chem 289, 28753-64
25204653   Curated Info

2

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

3

Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

4

Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info